Back to search results

Study of Communication Training for Large B-Cell Lymphoma Providers

This study is testing a new communication training called Hematolo-GIST. This training helps doctors (hematologists) talk with patients about their large B-cell lymphoma diagnosis and planning for future care. The study wants to see if this training is practical for doctors and patients. You might be able to join if you are an adult patient with large B-cell lymphoma and are currently being treated by a doctor who is part of this study. The study is looking to enroll 48 people in total. The current status of the study is unclear.

Study design
This is an interventional study, meaning participants will receive a specific intervention. It plans to enroll 48 participants, including both providers and patients.
What's involved
If you are a patient, you would meet with a hematologist who has received the Hematolo-GIST training. Your appointment would be audio-recorded on secure devices or platforms.
Compensation
Not stated in the trial record.
Follow-up
The study will look at the feasibility of the intervention for up to 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05940272

Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

Recruiting
NAAges 18+Interventional
Memorial Sloan Kettering Cancer Center
~48 participants
Updated 2025-10-09 on ClinicalTrials.gov
What's tested:Hematolo-GIST TrainingParticipants Appointment

At a glance

Recruiting sites
1 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Feasibility of the Hematolo-GIST intervention among hematologists and participants
Measured over Up to 1 year

Conditions

Lymphoma, B-Cell
Lymphoma
Large-cell Lymphoma
Large B-cell Lymphoma
DLBCL - Diffuse Large B Cell Lymphoma
Mediastinal B-Cell Diffuse Large Cell Lymphoma

Explore related trials

Diffuse Large B-Cell Lymphoma

NCT05940272

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Memorial Sloan Kettering Cancer Center (All protocol activities)

    New York, New Yorkstudy coordinator listed

    Recruiting

  • NEW YORK PRESBYTERIAN HOSPITAL (Data Collection Only)

    New York, New Yorkstudy coordinator listed

    Not yet recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Kelly McConnell, PhD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Kelly McConnell, PhD
[email protected]
646-888-0026
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Currently a an MSK provider caring for patients with DLBCL (including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and treated as large-cell lymphoma)
Per medical record, is currently being treated by a provider who is participating in this study (for the purposes of this study, "treating provider" will be defined as any provider who provides care related to the patient's lymphoma diagnosis)
Per medical record, has a diagnosis of DLBCL including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and clinically treated as large-cell lymphoma
Per medical record, relapse/ refractory disease within 12 months of 4 cycles of first line therapy OR relapse after 2 cycles of later line therapy or or autologous stem cell transplant (ASCT)
Self-identify as Black and/or White
Per medical record, 18 years of age or older
Per self-report, fluent in English\*\*
Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify English fluency necessary for participation in the study:

Exclusion

Per self-report, planning to leave the cancer center in the next 12 months
Cognitively impaired as demonstrated by (Blessed Orientation- Memory- Concentration (BOMC) score of ≥ 11
Per research staff judgment and/or self-report, too ill or weak to complete study procedures
Per medical record or self-report, receiving hospice care at the time of enrollment

What this trial measures

  • Feasibility of the Hematolo-GIST intervention among hematologists and participantsUp to 1 year

    Feasbility is defined as ≥70% of screened eligible hematologists and participants enrolling in the study and ≥80% of hematologists learning the approach